Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022

Rhea-AI Summary

Cybin, a biopharmaceutical company, will have CEO Doug Drysdale presenting at the KCSA Psychedelics Virtual Investor Conference on April 28, 2022, at 11:00 a.m. ET. This live online event allows investors to interact and ask questions directly. Cybin focuses on developing therapeutics using psychedelics to address mental health issues through innovative drug discovery platforms and treatment regimens. Investors can register for the event via the provided link and access the archived webcast later.

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™” is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the KCSA Psychedelics Virtual Investor Conference at 11:00 a.m. ET on Thursday, April 28, 2022.

This will be a live, interactive online event where investors are invited to ask the Company questions in real-time. To participate, please click here to register for the conference and access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.

About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220422005074/en/

Investor & Media Contacts:

Leah Gibson

Vice President, Investor Relations & Strategic Communications

Cybin Inc.

leah@cybin.com

Source: Cybin Inc.

FAQ

What is the date and time of Cybin's presentation at the KCSA Psychedelics Virtual Investor Conference?

Cybin's presentation is scheduled for April 28, 2022, at 11:00 a.m. ET.

Who will be presenting for Cybin at the conference?

Doug Drysdale, Cybin's Chief Executive Officer, will be presenting.

How can investors participate in the KCSA Psychedelics Virtual Investor Conference?

Investors can participate by registering through the provided link to join the live interactive event.

Where can I find the archived webcast of Cybin's presentation?

The archived webcast will be available on Cybin's investor relations website after the event.

What is the focus of Cybin as a biopharmaceutical company?

Cybin focuses on progressing psychedelics to therapeutics for addressing mental health issues.